Amarantus Bioscience Holdings, Inc.
Formerly Amarantus Bioscience, Inc., Amarantus Biosciences, Inc., Jumpkicks, Inc
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2014 | $3 M | No. 3 | $2 to $10 million | equity | SEC | |
| Sep 2013 | $1 M | No. 2 | Under $2 million | debt, options | SEC | |
| Aug 2013 | $1 M | No. 1 | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Amarantus Bioscience Holdings, Inc. had no revenue when it filed its newest notice of a funding round (Nov 2014).
SEC Form D (revenue range) · Nov 2014
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2014
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
3 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Gerald Commissiong | Person | not stated | not stated | Held Series C preferred stock (Form 3, 2014) | SEC Form 3 |
| John Wesley Commissiong | Person | not stated | not stated | Held Series C preferred stock, director (Form 3, 2015) | SEC Form 3 |
| Marc E. Faerber | Person | not stated | not stated | Held Series C preferred stock (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 5 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Gerald Commissiong | President and Chief Executive Officer | Nov 2014 |
| John Commissiong | Chief Scientific Officer and Director | Nov 2014 |
| Marc Faerber | Controller, Vice President of Financial Operations, Treasurer and Secretary | Nov 2014 |
| Robert Farrell | Chief Financial Officer | Nov 2014 |
| Dr. John W Commissiong | Executive officer | Sep 2013 |
| Gerald E Commissiong | Chief Executive Office | Sep 2013 |
| Marc E Faerber | Chief Financial Officer | Sep 2013 |
| David Lowe | Director | Nov 2014 |
| Donald Huffman | Director | Nov 2014 |
| Gerald Commissiong | President and Chief Executive Officer | Nov 2014 |
| Iain Ross | Director and Chairman of the Audit Committee | Nov 2014 |
| John Commissiong | Chief Scientific Officer and Director | Nov 2014 |
| Robert Harris | Director | Nov 2014 |
| Dr. John W Commissiong | Director | Sep 2013 |
| Gerald E Commissiong | Chief Executive Office | Sep 2013 |
| Mark E Benedyk | Director | Sep 2013 |
| Robert E Harris | Director | Sep 2013 |
| Mark L Benedyk | Director | Aug 2013 |
| Robert L Harris | Director | Aug 2013 |